Company intelligence / Profile preview

Priothera

Ownership: Private
Development stage: Phase 3

Overview

Priothera is conducting a pivotal MO-TRANS global Phase 2b/3 study evaluating mocravimod in AML patients undergoing allogeneic hematopoietic cell transplant (HCT). First patients were enrolled in January 2023, with topline results expected in 2025.

Therapeutic areas: Oncology
Modalities: Small moleculesS1P receptor modulators
Industry: Biotech

Drug pipeline

1 asset

mocravimod

Beyond the preview

Go deeper on Priothera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Priothera.

Explore the full profile